vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and POWER INTEGRATIONS INC (POWI). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $103.2M, roughly 1.5× POWER INTEGRATIONS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -1.9%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 6.1%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

American Electric Power Company, Inc. is an American domestic electric utility company in the United States. It is one of the largest electric utility companies in the country, with more than five million customers in 11 states.

BCRX vs POWI — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.5× larger
BCRX
$156.4M
$103.2M
POWI
Growing faster (revenue YoY)
BCRX
BCRX
+9.4% gap
BCRX
7.5%
-1.9%
POWI
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
6.1%
POWI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCRX
BCRX
POWI
POWI
Revenue
$156.4M
$103.2M
Net Profit
$13.3M
Gross Margin
52.9%
Operating Margin
13.6%
8.5%
Net Margin
12.9%
Revenue YoY
7.5%
-1.9%
Net Profit YoY
45.4%
EPS (diluted)
$0.00
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
POWI
POWI
Q1 26
$156.4M
Q4 25
$406.6M
$103.2M
Q3 25
$159.4M
$118.9M
Q2 25
$163.4M
$115.9M
Q1 25
$145.5M
$105.5M
Q4 24
$131.5M
$105.3M
Q3 24
$117.1M
$115.8M
Q2 24
$109.3M
$106.2M
Net Profit
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
$245.8M
$13.3M
Q3 25
$12.9M
$-1.4M
Q2 25
$5.1M
$1.4M
Q1 25
$32.0K
$8.8M
Q4 24
$-26.8M
$9.1M
Q3 24
$-14.0M
$14.3M
Q2 24
$-12.7M
$4.8M
Gross Margin
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
97.7%
52.9%
Q3 25
98.6%
54.5%
Q2 25
98.3%
55.2%
Q1 25
96.9%
55.2%
Q4 24
95.4%
54.4%
Q3 24
97.3%
54.5%
Q2 24
98.4%
53.2%
Operating Margin
BCRX
BCRX
POWI
POWI
Q1 26
13.6%
Q4 25
64.0%
8.5%
Q3 25
18.6%
-3.3%
Q2 25
18.2%
-1.2%
Q1 25
14.6%
6.4%
Q4 24
-3.4%
3.7%
Q3 24
6.6%
10.0%
Q2 24
8.0%
1.8%
Net Margin
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
60.5%
12.9%
Q3 25
8.1%
-1.1%
Q2 25
3.1%
1.2%
Q1 25
0.0%
8.3%
Q4 24
-20.4%
8.7%
Q3 24
-12.0%
12.3%
Q2 24
-11.6%
4.6%
EPS (diluted)
BCRX
BCRX
POWI
POWI
Q1 26
$0.00
Q4 25
$1.13
$0.24
Q3 25
$0.06
$-0.02
Q2 25
$0.02
$0.02
Q1 25
$0.00
$0.15
Q4 24
$-0.13
$0.15
Q3 24
$-0.07
$0.25
Q2 24
$-0.06
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
POWI
POWI
Cash + ST InvestmentsLiquidity on hand
$259.0M
$249.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$672.8M
Total Assets
$465.1M
$772.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
POWI
POWI
Q1 26
$259.0M
Q4 25
$274.7M
$249.5M
Q3 25
$212.9M
$241.9M
Q2 25
$260.0M
$268.7M
Q1 25
$295.1M
$289.3M
Q4 24
$320.9M
$300.0M
Q3 24
$96.8M
$303.8M
Q2 24
$78.4M
$290.5M
Stockholders' Equity
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
$-119.2M
$672.8M
Q3 25
$-387.9M
$672.0M
Q2 25
$-421.6M
$703.8M
Q1 25
$-451.9M
$735.8M
Q4 24
$-475.9M
$749.8M
Q3 24
$-468.6M
$749.2M
Q2 24
$-475.6M
$730.7M
Total Assets
BCRX
BCRX
POWI
POWI
Q1 26
$465.1M
Q4 25
$514.2M
$772.2M
Q3 25
$446.4M
$772.5M
Q2 25
$457.2M
$797.5M
Q1 25
$480.0M
$814.4M
Q4 24
$490.4M
$828.8M
Q3 24
$491.3M
$825.0M
Q2 24
$472.4M
$804.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
POWI
POWI
Operating Cash FlowLast quarter
$26.2M
Free Cash FlowOCF − Capex
$19.2M
FCF MarginFCF / Revenue
18.6%
Capex IntensityCapex / Revenue
6.8%
Cash ConversionOCF / Net Profit
1.97×
TTM Free Cash FlowTrailing 4 quarters
$87.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
$292.0M
$26.2M
Q3 25
$41.6M
$29.9M
Q2 25
$41.3M
$29.1M
Q1 25
$-27.5M
$26.4M
Q4 24
$-5.2M
$14.7M
Q3 24
$8.2M
$32.9M
Q2 24
$-1.4M
$17.6M
Free Cash Flow
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
$291.2M
$19.2M
Q3 25
$40.3M
$24.2M
Q2 25
$41.1M
$23.1M
Q1 25
$-27.7M
$20.7M
Q4 24
$-5.9M
$11.7M
Q3 24
$8.2M
$27.2M
Q2 24
$-1.5M
$13.5M
FCF Margin
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
71.6%
18.6%
Q3 25
25.3%
20.3%
Q2 25
25.2%
20.0%
Q1 25
-19.0%
19.6%
Q4 24
-4.5%
11.1%
Q3 24
7.0%
23.5%
Q2 24
-1.4%
12.7%
Capex Intensity
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
0.2%
6.8%
Q3 25
0.8%
4.8%
Q2 25
0.1%
5.1%
Q1 25
0.1%
5.4%
Q4 24
0.5%
2.9%
Q3 24
0.1%
4.9%
Q2 24
0.1%
3.9%
Cash Conversion
BCRX
BCRX
POWI
POWI
Q1 26
Q4 25
1.19×
1.97×
Q3 25
3.23×
Q2 25
8.12×
21.24×
Q1 25
-859.91×
3.00×
Q4 24
1.61×
Q3 24
2.30×
Q2 24
3.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

POWI
POWI

Distributors$65.8M64%
Other$10.3M10%
KR$9.3M9%
DE$7.1M7%
TW$5.5M5%
Emea Other Than Germany$5.3M5%

Related Comparisons